Although two studies have reported that miR-203 inhibits ovarian tumor metastasis by targeting BIRC5, attenuating the TGFβ pathway, and inhibiting epithelial to mesenchymal transition [26, 27], one of these studies did not examine the expression of miR-203 in clinical ovarian cancer samples, and the other study was performed using human ovarian serous carcinoma tissues. Here, BIRC5 is linked to ovarian cancer.